Bluelight (web forum)

Last updated
Bluelight.org
NicknameBluelight
PredecessorMDMA Clearinghouse
Formation1997;27 years ago (1997)
Legal statusNon-profit organization
Purpose Harm reduction, peer support, academic research, mental health, drug education, substance dependence recovery
HeadquartersMelbourne, Australia
Region served
International
Membership
475,000 (June 2024)
Official language
English
Executive Director
Monica J. Barratt
Parent organization
Bluelight Communities Ltd.
Affiliations Multidisciplinary Association for Psychedelic Studies
Erowid
Tripsit
PillReports.net
Volunteers
50+
Website www.bluelight.org
Formerly called
Bluelight.ru, Bluelight.nu

Bluelight is a web-forum, research portal, online community, and non-profit organization dedicated to harm reduction in drug use. [1] [2] Its userbase includes current and former substance users, academic researchers, drug policy activists, and mental health advocates. [2] [3] [4] It is believed to be the largest online international drug discussion website in the world. [1] [5] As of February 2024, the website claims over 465,000 registered members. [6]

Contents

Bluelight has been utilized by academic researchers as a primary source of data in numerous publications. [1] [2] [7] [8] [9] Researchers also utilize the site to advertise research studies, recruit study participants, and better understand the world of substance use. [1] [2] Research groups and organizations that have partnered with Bluelight to recruit study participants include Imperial College London, [10] [11] Johns Hopkins University, [12] [13] [14] Health Canada, [15] Karlstad University, [16] Curtin University, [17] Macquarie University, [18] Columbia University, [19] [20] University of Pennsylvania, [21] University of Michigan, [22] [23] [24] [25] [26] [27] Toronto Metropolitan University (then known as Ryerson University), [28] and MAPS. [29]

Researchers have found that the most common reasons for substance users to visit Bluelight.org and similar online communities are to learn "how to use drugs safely" and "how to help others use drugs safely." [2] [22] [30]

Bluelight does not condemn or condone drug use, but instead advocates educating individuals to make informed decisions, connecting them with local harm reduction services, and providing them with evidence-based harm reduction resources and public safety notices. Bluelight emphasizes "meeting users where they are", and supporting them whether they wish to continue, moderate, or cease their substance use. [8] [30] [31]

In 2022, Bluelight launched an expansion to various social media platforms, most notably establishing a community on the instant messaging platform Discord dedicated to harm reduction, mental health, & peer support. [32] [33] As of June 2024, its Discord community is home to over 8,500 members. [33]

History

Bluelight.org was originally formed in 1997 as a message board on bluelight.net called the MDMA Clearinghouse. [34] The board was created as a side project by the owner of West Palm Beach design company Bluelight Designs. [35] 200-300 users joined the site between 1998-1999, but the site's servers were heavily limited and could only store a few threads at a time; this led to the creation of 'The New Bluelight' forum in May 1999 and the registration of the bluelight.nu domain in June 1999. [34]

The site began to explode in popularity in the early 2000s with the rise of MDMA in the club scene, amassing nearly 7,000 members by the year 2000 and 59,000 by the start of 2006. [34] [36]

The site switched to the bluelight.ru domain in October 2005, and switched again to bluelight.org in January 2014. [35]

In February 2022, Bluelight launched a social media initiative and spearheaded an expansion to other platforms. [32] The centerpiece of this expansion is a Discord community dedicated to harm reduction, mental health, & peer support. [33] The community brands itself as "a safe haven for people who are LGBTQIA+, neurodivergent, substance users, struggling with mental health, or just don't feel like they fit in anywhere else." [31]

In early 2024, Bluelight became a subsidiary of the Australian non-profit organization Bluelight Communities Ltd. [37]

Partnerships

In the early 2000s, Bluelight worked with reagent test supplier EZ-Test to promote the sale of drug checking kits.

In 2007, Bluelight partnered with the Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit organization working to raise awareness and understanding of psychedelic drugs through education, clinical research, and advocacy. [29] [34] MAPS utilized Bluelight to recruit participants for its first MDMA-assisted psychotherapy trial for PTSD. In 2013, the official MAPS forums were migrated to Bluelight. [38]

Bluelight's other partners include Erowid, a non-profit organization dedicated to education surrounding psychoactive drugs; Tripsit, a harm reduction education website; Pill Reports, a web-based database for drug checking results that was initially formed as an offshoot of the site; and the Global Drug Survey, an independent research organization focused on collecting data about substance use.

Notable users

See also

Related Research Articles

<span class="mw-page-title-main">Ayahuasca</span> South American psychoactive brew

Ayahuasca is a South American psychoactive beverage, traditionally used by Indigenous cultures and folk healers in the Amazon and Orinoco basins for spiritual ceremonies, divination, and healing a variety of psychosomatic complaints.

<span class="mw-page-title-main">MDMA</span> Psychoactive drug, often called ecstasy

3,4-Methyl​enedioxy​methamphetamine (MDMA), commonly known as ecstasy, and molly, is an empathogen–entactogenic drug with stimulant and minor psychedelic properties. In studies, it has been used alongside psychotherapy in the treatment of post-traumatic stress disorder (PTSD) and social anxiety in autism spectrum disorder. The purported pharmacological effects that may be prosocial include altered sensations, increased energy, empathy, and pleasure. When taken by mouth, effects begin in 30 to 45 minutes and last three to six hours.

<span class="mw-page-title-main">Mescaline</span> Naturally occurring psychedelic compound

Mescaline, also known as mescalin or mezcalin, as well as 3,4,5-trimethoxyphenethylamine, is a naturally occurring psychedelic protoalkaloid of the substituted phenethylamine class, known for its hallucinogenic effects comparable to those of LSD and psilocybin. It binds to and activates certain serotonin receptors in the brain, producing hallucinogenic effects.

<span class="mw-page-title-main">Harm reduction</span> Public health policies which lessen negative aspects of problematic activities

Harm reduction, or harm minimization, refers to a range of intentional practices and public health policies designed to lessen the negative social and/or physical consequences associated with various human behaviors, both legal and illegal. Harm reduction is used to decrease negative consequences of recreational drug use and sexual activity without requiring abstinence, recognizing that those unable or unwilling to stop can still make positive change to protect themselves and others.

<span class="mw-page-title-main">Psilocybin mushroom</span> Mushrooms containing psychoactive indole alkaloids

Psilocybin mushrooms, commonly known as magic mushrooms,shrooms, or broadly as hallucinogenic mushrooms, are a polyphyletic informal group of fungi that contain psilocybin, which turns into psilocin upon ingestion. The most potent species are members of genus Psilocybe, such as P. azurescens, P. semilanceata, and P. cyanescens, but psilocybin has also been isolated from approximately a dozen other genera, including Panaeolus, Inocybe, Pluteus, Gymnopilus, and Pholiotina.

<span class="mw-page-title-main">Ergine</span> Chemical compound

Ergine, also known as d-lysergic acid amide (LSA) and d-lysergamide, is an ergoline alkaloid that occurs in various species of vines of the Convolvulaceae and some species of fungi. The psychedelic properties in the seeds of ololiuhqui, Hawaiian baby woodrose and morning glories have been linked to ergine and/or isoergine, its epimer, as it is an alkaloid present in the seeds.

<span class="mw-page-title-main">5-MeO-DMT</span> Chemical compound

5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), also known as O-methylbufotenin or mebufotenin, is a psychedelic of the tryptamine family. It is found in a wide variety of plant species, and also is secreted by the glands of at least one toad species, the Colorado River toad. Like its close relatives dimethyltryptamine (DMT) and bufotenin (5-HO-DMT), it has been used as an entheogen in South America. Slang terms include Five-methoxy, the power, bufo, and toad venom.

<span class="mw-page-title-main">Erowid</span> Non-profit educational organization

Erowid, also called Erowid Center, is a non-profit educational organization that provides information about psychoactive plants and chemicals.

Psychedelic therapy refers to the proposed use of psychedelic drugs, such as psilocybin, ayahuasca, LSD, psilocin, mescaline (peyote), DMT, 5-MeO-DMT,Ibogaine,MDMA, to treat mental disorders. As of 2021, psychedelic drugs are controlled substances in most countries and psychedelic therapy is not legally available outside clinical trials, with some exceptions.

<span class="mw-page-title-main">Set and setting</span> Mindset and location of a drug experience

Set and setting, when referring to a psychedelic drug experience or the use of other psychoactive substances, means one's mindset and the physical and social environment in which the user has the experience. Set and setting are factors that can condition the effects of psychoactive substances: "Set" refers to the mental state a person brings to the experience, like thoughts, mood and expectations; "setting" to the physical and social environment. This is especially relevant for psychedelic experiences in either a therapeutic or recreational context.

The Multidisciplinary Association for Psychedelic Studies (MAPS) is an American nonprofit organization working to raise awareness and understanding of psychedelic substances. MAPS was founded in 1986 by Rick Doblin and is now based in San Jose, California.

Drug education is the planned provision of information, guidelines, resources, and skills relevant to living in a world where psychoactive substances are widely available and commonly used for a variety of both medical and non-medical purposes, some of which may lead to harms such as overdose, injury, infectious disease, or addiction. The two primary approaches to drug education are harm-reduction education and abstinence-based education.

<span class="mw-page-title-main">Polysubstance use</span> Use of multiple psychoactive substances

Polysubstance use or poly drug use refers to the use of combined psychoactive substances. Polysubstance use may be used for entheogenic, recreational, or off-label indications, with both legal and illegal substances. In many cases one drug is used as a base or primary drug, with additional drugs to leaven or compensate for the side effects, or tolerance, of the primary drug and make the experience more enjoyable with drug synergy effects, or to supplement for primary drug when supply is low.

Sex and drugs refers to the influence of substances on sexual function and experience. Sex and drugs date back to ancient humans and have been interlocked throughout human history. Sexual performance is known as the execution of the act of sex and the quality of sexual activity. This includes elements such as libido, sexual function, sensation. Drugs are termed as any chemical substance that produces a physiological and or psychological change in an organism. Drugs categorized as psychoactive drugs, antihypertensive drugs, antihistamines, cancer treatment, and hormone medication have a significant impact on sexual performance. Various drugs result in different effects, both positive and negative. Negative effects may include low libido, erection issues, vaginal dryness and anorgasmia. Positive effects usually address these issues, overall enhancing sexual performance and contributing to a more enjoyable sexual experience. It is crucial to know that the impact of drugs on sexual performance varies among individuals, especially among different genders.

<span class="mw-page-title-main">Drug</span> Substance having effect(s) on the body of an individual

A drug is any chemical substance other than a nutrient or an essential dietary ingredient, which, when administered to a living organism, produces a biological effect. Consumption of drugs can be via inhalation, injection, smoking, ingestion, absorption via a patch on the skin, suppository, or dissolution under the tongue.

<span class="mw-page-title-main">4-HO-MET</span> Chemical compound

4-HO-MET is a lesser-known psychedelic drug. It is a structural and functional analog of psilocin as well as the 4-hydroxyl analog of methylethyltryptamine (MET). 4-HO-MET was first synthesized by Alexander Shulgin. In his book TiHKAL, the dosage is listed as 10-20 mg. 4-HO-MET produces psilocin-like distortion of color, sound, and form. Very little data exists about the pharmacological properties, metabolism, and toxicity of 4-HO-MET. There have been no reports of deaths from 4-HO-MET, even though there exist anecdotal reports of the ingestion of up to 150 mg, more than an order of magnitude above the effective dose.

<span class="mw-page-title-main">Psychoactive drug</span> Chemical substance that alters brain function

A psychoactive drug, mind-altering drug, or consciousness-altering drug is a chemical substance that changes brain function and results in alterations in perception, mood, consciousness, cognition, or behavior. The term psychotropic drug is often used interchangeably, while some sources present narrower definitions. These substances may be used medically; recreationally; to purposefully improve performance or alter consciousness; as entheogens for ritual, spiritual, or shamanic purposes; or for research, including psychedelic therapy. Physicians and other healthcare practitioners prescribe psychoactive drugs from several categories for therapeutic purposes. These include anesthetics, analgesics, anticonvulsant and antiparkinsonian drugs as well as medications used to treat neuropsychiatric disorders, such as antidepressants, anxiolytics, antipsychotics, and stimulants. Some psychoactive substances may be used in detoxification and rehabilitation programs for persons dependent on or addicted to other psychoactive drugs.

<span class="mw-page-title-main">Psychedelic microdosing</span> Drug experimentation technique

Psychedelic microdosing involves consuming sub-threshold doses (microdoses) of serotonergic psychedelic drugs like LSD and psilocybin to potentially enhance creativity, energy, emotional balance, problem-solving abilities, and to address anxiety, depression, and addiction. This practice has gained popularity in the 21st century. A June 2024 report by the RAND Corporation suggests that among adults in the United States reporting the use of psilocybin in the past year, nearly half reported microdosing the last time they used it.

Drug checking or pill testing is a way to reduce the harm from drug consumption by allowing users to find out the content and purity of substances that they intend to consume. This enables users to make safer choices: to avoid more dangerous substances, to use smaller quantities, and to avoid dangerous combinations.

References

  1. 1 2 3 4 Anderson, Laurie S.; Bell, Heidi G; Gilbert, Michael; Davidson, Julie E; Winter, Christina; Barratt, Monica J; Win, Beta; Painter, Jeffery L; Menone, Christopher; Sayegh, Jonathan; Dasgupta, Nabarun (2017-02-01). "Using Social Listening Data to Monitor Misuse and Nonmedical Use of Bupropion: A Content Analysis". JMIR Public Health and Surveillance. 3 (1): e6. doi: 10.2196/publichealth.6174 . ISSN   2369-2960. PMC   5311422 . PMID   28148472.
  2. 1 2 3 4 5 Chiauzzi, Emil; Dasmahapatra, Pronabesh; Lobo, Kimberly; Barratt, Monica J. (June 2013). "Participatory research with an online drug forum: a survey of user characteristics, information sharing, and harm reduction views". Substance Use & Misuse. 48 (8): 661–670. doi:10.3109/10826084.2013.800117. hdl: 1959.4/unsworks_73353 . ISSN   1532-2491. PMID   23750771. S2CID   207520485. Archived from the original on 2024-02-05. Retrieved 2024-02-05.
  3. ↑ Aubusson, Kate (2016-11-16). "Drug users swap stories, share warnings online in search for safety". The Sydney Morning Herald. Archived from the original on 2020-11-14. Retrieved 2020-11-14.
  4. ↑ Johnson, Doug (2019-10-18). "To Tackle Drug Use, Researchers and People With Addiction Alike Turn to Online Forums". Undark Magazine. Archived from the original on 2021-09-16. Retrieved 2020-11-14.
  5. ↑ "Site Info". Alexa. 2016. Archived from the original on February 20, 2017. Retrieved January 16, 2017.
  6. ↑ "Forum list". Bluelight.org. 2024-02-04. Archived from the original on 2024-02-05. Retrieved 2024-02-04.
  7. ↑ Ward, Jeanine; Rhyee, Sean; Plansky, Jason; Boyer, Edward (November 2011). "Methoxetamine: a novel ketamine analog and growing health-care concern". Clinical Toxicology. 49 (9): 874–875. doi:10.3109/15563650.2011.617310. ISSN   1556-9519. PMID   21981756. S2CID   28388437. Archived from the original on 2024-02-05. Retrieved 2024-02-05.
  8. 1 2 Barratt, Monica J.; Allen, Matthew; Lenton, Simon (June 2014). ""PMA sounds fun": negotiating drug discourses online". Substance Use & Misuse. 49 (8): 987–998. doi:10.3109/10826084.2013.852584. hdl: 20.500.11937/35817 . ISSN   1532-2491. PMID   24779498. S2CID   41509447. Archived from the original on 2024-02-05. Retrieved 2024-02-05.
  9. ↑ Deluca, Paolo; Davey, Zoe; Corazza, Ornella; Di Furia, Lucia; Farre, Magi; Flesland, Liv Holmefjord; Mannonen, Miia; Majava, Aino; Peltoniemi, Teuvo; Pasinetti, Manuela; Pezzolesi, Cinzia; Scherbaum, Norbert; Siemann, Holger; Skutle, Arvid; Torrens, Marta; Van Der Kreeft, Peer; Iversen, Erik; Schifano, Fabrizio (2012-12-03). "Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 39 (2): 221–226. doi:10.1016/j.pnpbp.2012.07.011. ISSN   0278-5846. PMID   22841965. S2CID   22296279. Archived from the original on 2024-02-05. Retrieved 2024-02-05.
  10. ↑ Carhart-Harris, R. L.; King, L. A.; Nutt, D. J. (2011-10-01). "A web-based survey on mephedrone". Drug and Alcohol Dependence. 118 (1): 19–22. doi:10.1016/j.drugalcdep.2011.02.011. ISSN   1879-0046. PMID   21420252. Archived from the original on 2024-02-05. Retrieved 2024-02-05.
  11. ↑ Kettner, H.; Rosas, F. E.; Timmermann, C.; Kärtner, L.; Carhart-Harris, R. L.; Roseman, L. (2021). "Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness". Frontiers in Pharmacology. 12. doi: 10.3389/fphar.2021.623985 . ISSN   1663-9812. PMC   8114773 . PMID   33995022.
  12. ↑ Davis, Alan K; Clifton, John M; Weaver, Eric G; Hurwitz, Ethan S; Johnson, Matthew W; Griffiths, Roland R (September 2020). "Survey of entity encounter experiences occasioned by inhaled N,N -dimethyltryptamine: Phenomenology, interpretation, and enduring effects". Journal of Psychopharmacology. 34 (9): 1008–1020. doi: 10.1177/0269881120916143 . ISSN   0269-8811. PMID   32345112.
  13. ↑ "Completed - Quick survey on the interactions between psilocybin mushrooms and antidepressants". Bluelight.org. 2020-09-25. Archived from the original on 2024-02-05. Retrieved 2024-02-05.
  14. ↑ "Recruiting - Johns Hopkins survey on HPPD: Help us uncover new insights into the condition and its treatment". Bluelight.org. 2023-05-23. Archived from the original on 2024-02-05. Retrieved 2024-02-05.
  15. ↑ Young, Matthew M.; Dubeau, Chad; Corazza, Ornella (2015-02-16). "Detecting a signal in the noise: monitoring the global spread of novel psychoactive substances using media and other open-source information". Human Psychopharmacology: Clinical and Experimental. 30 (4) (published 2015-07-28): 319–326. doi:10.1002/hup.2477. ISSN   0885-6222. PMC   4584493 . PMID   26216568.
  16. ↑ Soussan, Christophe; Kjellgren, Anette (2016-06-01). "The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations". International Journal of Drug Policy. 32: 77–84. doi:10.1016/j.drugpo.2016.03.007. ISSN   0955-3959. PMID   27184218. Archived from the original on 2024-02-05. Retrieved 2024-02-05.
  17. ↑ Barratt, Monica J.; Cakic, Vince; Lenton, Simon (March 2013). "Patterns of synthetic cannabinoid use in Australia". Drug and Alcohol Review. 32 (2): 141–146. doi:10.1111/j.1465-3362.2012.00519.x. hdl: 1959.4/unsworks_73313 . ISSN   0959-5236. PMID   23043552. Archived from the original on 2024-02-05. Retrieved 2024-02-05.
  18. ↑ Polito, Vince; Stevenson, Richard J. (2019-02-06). "A systematic study of microdosing psychedelics". PLOS ONE. 14 (2): e0211023. Bibcode:2019PLoSO..1411023P. doi: 10.1371/journal.pone.0211023 . ISSN   1932-6203. PMC   6364961 . PMID   30726251.
  19. ↑ "Recruiting - Anonymous Survey Study on Psychedelic Use in Romantic Relationships - Columbia University". Bluelight.org. 2022-05-16. Archived from the original on 2024-02-05. Retrieved 2024-02-05.
  20. ↑ "Recruiting - RESEARCH VOLUNTEERS: Healthy heroin users". Bluelight.org. 2022-12-23. Archived from the original on 2024-02-05. Retrieved 2024-02-05.
  21. ↑ "Recruiting - [USA] Community Health Discussion Session/Survey Study (Reimbursement up to $225)". Bluelight.org. 2023-09-21. Archived from the original on 2024-02-05. Retrieved 2024-02-05.
  22. 1 2 Kruger, Daniel J.; Enghoff, Oskar; Herberholz, Moss; Barron, Julie; Boehnke, Kevin F. (2023-10-20). ""How Do I Learn More About this?": Utilization and Trust of Psychedelic Information Sources Among People Naturalistically Using Psychedelics". Journal of Psychoactive Drugs. 55 (5): 631–639. doi:10.1080/02791072.2023.2201263. ISSN   0279-1072. PMID   37078418. S2CID   258237524. Archived from the original on 2024-02-05. Retrieved 2024-02-05.
  23. ↑ Glynos, Nicolas G.; Fields, Christopher W.; Barron, Julie; Herberholz, Moss; Kruger, Daniel J.; Boehnke, Kevin F. (2023-08-08). "Naturalistic Psychedelic Use: A World Apart from Clinical Care". Journal of Psychoactive Drugs. 55 (4): 379–388. doi:10.1080/02791072.2022.2108356. ISSN   0279-1072. PMID   35950817. S2CID   251494820. Archived from the original on 2024-02-05. Retrieved 2024-02-05.
  24. ↑ Kruger, Daniel J.; Glynos, Nicolas G.; Fields, Christopher W.; Herberholz, Moss; Boehnke, Kevin F. (2023-08-08). "An Assessment of Psychedelic Knowledge Among People Using Psychedelics Naturalistically". Journal of Psychoactive Drugs. 55 (4): 420–424. doi:10.1080/02791072.2022.2142709. ISSN   0279-1072. PMID   36328419. S2CID   253303071. Archived from the original on 2024-02-05. Retrieved 2024-02-05.
  25. ↑ Kruger, Daniel J.; Barron, Julie; Herberholz, Moss; Boehnke, Kevin F. (2023-10-20). "Preferences and Support for Psychedelic Policies and Practices Among Those Using Psychedelics". Journal of Psychoactive Drugs. 55 (5): 650–659. doi:10.1080/02791072.2023.2228784. ISSN   0279-1072. PMID   37353935. S2CID   259240648. Archived from the original on 2024-02-05. Retrieved 2024-02-05.
  26. ↑ Boehnke, Kevin F.; Cox, Kasey; Weston, Cody; Herberholz, Moss; Glynos, Nicolas; Kolbman, Nicholas; Fields, Christopher W.; Barron, Julie; Kruger, Daniel J. (2023). "Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers". Frontiers in Psychiatry. 14. doi: 10.3389/fpsyt.2023.1224551 . ISSN   1664-0640. PMC   10436225 . PMID   37599880.
  27. ↑ "Recruiting - Amplifying Community Voices Through Science — We want to hear about YOUR experiences with psychedelics". Bluelight.org. 2023-10-27. Archived from the original on 2024-02-05. Retrieved 2024-02-05.
  28. ↑ "Writing-up - Psychedelic Drug Experiences Survey". Bluelight.org. 2020-03-04. Archived from the original on 2024-02-05. Retrieved 2024-02-05.
  29. 1 2 "Bluelight - MAPS.org partnership!". Bluelight.org. 2007-02-14. Archived from the original on 2024-02-05. Retrieved 2024-02-04.
  30. 1 2 Pereira, Margaret; Scott, John (2017-01-02). "Harm reduction and the ethics of drug use: contemporary techniques of self-governance". Health Sociology Review. 26 (1): 69–83. doi:10.1080/14461242.2016.1184583. ISSN   1446-1242. S2CID   148474622. Archived from the original on 2024-02-05. Retrieved 2024-02-05.
  31. 1 2 "Bluelight.org". Discord Servers. Archived from the original on 2024-02-05. Retrieved 2024-02-04.
  32. 1 2 "Bluelight Social Media Links + Discord". Bluelight.org. 2022-02-10. Archived from the original on 2024-02-05. Retrieved 2024-02-04.
  33. 1 2 3 "Bluelight.org - Discord Servers". Discord. Archived from the original on 2024-02-05. Retrieved 2024-02-04.
  34. 1 2 3 4 5 Nichols, Sam (2019-05-06). "How 'Bluelight' Became a Life-Saving Encyclopedia of Drug Info". Vice. Archived from the original on 2024-03-01. Retrieved 2024-03-01.
  35. 1 2 "Bluelight History". Bluelight.org. Archived from the original on 2024-02-05. Retrieved 2024-02-04.
  36. ↑ "Bluelight - Powered by vBulletin". 2006-01-01. Archived from the original on 2006-01-01. Retrieved 2024-03-01.
  37. ↑ "New website and branding for Bluelight has landed!". Bluelight.org. 2024-03-08. Archived from the original on 2024-03-18. Retrieved 2024-03-18.
  38. ↑ "Bluelight Announcement". MAPS. 5 April 2013. Archived from the original on 2021-10-21. Retrieved 2020-11-14.
  39. ↑ Simonini, Ross (2012-02-10). "A Psychonaut's Adventures in Videoland". The New York Times. ISSN   0362-4331. Archived from the original on 2012-02-13. Retrieved 2024-02-29.
  40. ↑ Davis, Joshua. "John McAfee Fled to Belize, But He Couldn't Escape Himself". Wired. ISSN   1059-1028. Archived from the original on 2024-02-23. Retrieved 2024-02-29.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.